Anti-TNF and Crohn's disease: When should we stop?

Current Drug Targets

Volumn 11, Issue 2, 2010, Pages 148-151

  Louis, Edouard ^a   Belaiche, Jacques ^a   Reenaers, Catherine ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Adalimumab; Biomarkers; Certolizumab pegol; Crohn's disease; Infliximab; Mucosal healing; Therapy

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; PLACEBO; STEROID; TUMOR NECROSIS FACTOR INHIBITOR;

COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; HEPATOSPLENIC T CELL LYMPHOMA; HISTOPLASMOSIS; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LONG TERM CARE; LYMPHOMA; MONOTHERAPY; MORTALITY; MYCOBACTERIOSIS; OPPORTUNISTIC INFECTION; REMISSION; REVIEW; RISK BENEFIT ANALYSIS; T CELL LYMPHOMA; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; TUBERCULOSIS;

ANTI-INFLAMMATORY AGENTS; BIOLOGICAL PRODUCTS; COST-BENEFIT ANALYSIS; CROHN DISEASE; HUMANS; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77950843556     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945010790309957     Document Type: Review

References (42)

1. Hanauer S, Feagan B, Lichtenstein G, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549 (Pubitemid 34621118)
2. Colombel J, Sandborn W, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65. (Pubitemid 46108762)
3. Schreiber S, Khaliq-Kareemi M, Lauwrance I, Thomsen OØ, Hanauer SB, McColm J, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007; 357: 239-250 (Pubitemid 47080388)
4. Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995; 30: 699-706.
5. Wolters FL, Russel MG, Sijbrandij J, Ambergen T, Odes S, Riis L, et al. Phenotype at diagnosis predicts recurrence rates in Crohn's disease. Gut 2006; 55: 1124-1130
6. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn's disease. Gastroenterology 2006; 130: 650-656
7. Loly C, Belaiche J, Louis E. Predictors of severe Crohn's disease. Scand J Gastroenterol 2008; 43: 948-954
8. Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J. Behaviour of Crohn's disease according to the Vienna Classification: changing pattern over the course of the disease. Gut 2001; 49: 777-782 (Pubitemid 33096034)
9. Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, et al. Long-term evolution of disease behaviour of Crohn's disease. Inflamm Bowel Dis 2002; 8: 244-250 (Pubitemid 34784976)
10. Kugathasan S , Saubermann L, Smith L, Kou D, Itoh J, Binion DG, et al. Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease. Gut 2007; 56: 1696-1705. (Pubitemid 350206296)
11. Dubinsky M, Kugathasan S, Mei L, Picornell Y, Nebel J, Wrobel IT, et al. Increased immune reactivity predicts aggressive complicating Crohn's disease in Children. Clin Gastroenterol Hepatol 2008; 6: 1105-1111
12. Rieder F, Schleder S, Wolf A, Dirmeier A, Strauch U, Obermeier F, et al. Specific levels and combinations of the anti-glycan antibodies anti-L, anti-C, ALCA, ACCA, gASCA and AMCA contribute to diagnosis and differential diagnosis of patients with Crohn's disease and are associated with complicated disease and surgery. Gastroenterology 2008; 134(A-53): 392.
13. Ferrante M, Henckaerts L, Joossens M, Pierik M, Joossens S, Dotan N, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 2007; 56: 1394-1403 (Pubitemid 47517833)
14. Schreiber S, Hanauer S, Lichtenstein G, Sandborn W. Superior efficacy of certolizumab pegol in early Crohn's disease is independent of CRP status. Gastroenterology 2007; 132(A-510): T1298.
15. Colombel JF, Rutgeerts P, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. A randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gut 2008; 57(sII): A1.
16. Bouhnik Y, Lémann M, Mary JY, Scemama G, Taï R, Matuchansky C, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996; 347: 215-219 (Pubitemid 26035245)
17. Lémann M, Mary JY, Colombel JF, Duclos B, Soule JC, Lerebours E, et al. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 2005; 128: 1812-1908
18. Treton X, Bouhnik Y, Mary JY, Colombel JF, Duclos B, Soule JC, et al. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol 2009; 7: 80-85
19. Keane J, Gershon S, Wise R, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-1104
20. Siegel C, Sadie M, Marden S, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with anti-TNF agents for the treatment of Crohn's disease: a meta-analysis. Gastroenterology 2008; 134(A-144): 970.
21. Rahier JF, Ben-Horin S, Chowers Y, Conlon C, De Munter P, D'Haens G, et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn's colitis 2009; 3: 47-91.
22. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, Baert F, Noman M, Vermeire S, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008; 134: 1861-1868 (Pubitemid 351790744)
23. Toruner M, Loftus E, Harmsen W, Zinsmeister AR, Orenstein R, Sandborn WJ, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134: 929-936 (Pubitemid 351451967)
24. Mackey A, Green L, Liang L, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44: 265-267 (Pubitemid 46175082)
25. Targan S, Hanauer S, Van Deventer S, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-1035 (Pubitemid 27430520)
26. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, et al. Efficacy and safety of retreatment with antitumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117: 761-769 (Pubitemid 29468216)
27. Lémann M, Mary JY, Duclos B, Veyrac M, Dupas JL, Delchier JC, et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006; 130: 1054-1061
28. Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009; 58: 492-500.
29. Louis E, Vernier-Massouille G, Grimaud J, Bouhnik Y, Laharie D, Dupas JL, et al. Infliximab discontinuation in Crohn's disease patients in stable remission of combined therapy with immunosuppressors: interim analysis of a prospective cohort study. Gut 2008; 57 (sII): A66.
30. Hay JW, Hay AR. Inflammatory bowel disease: medical cost algorithms. J Clin Gastroenterol 1992; 14: 318-327
31. Feagan BG, Vreelad MG, Larson LR, Bala MV. Annual cost of care for Crohn's disease: a payer perspective. Am J Gastroenterol 2000; 95: 1955-1960
32. Silverstein MD, Loftus EV, Sandborn WJ, Tremaine WJ, Feagan BG, Nietert PJ, et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 1999; 117: 49-57.
33. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126: 402-413 (Pubitemid 38182297)
34. Loftus EV, Feagan BG, Colombel JF, Rubin DT, Wu EQ, Yu AP, et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol 2008; 103: 3132-3141
35. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 661-665 (Pubitemid 39276479)
36. Louis E, Belaiche J, Van Kemseke C, De Groote D, Geenen V, Mary JY. Concentration of interleukin-6 in the serum predicts relapse in Crohn's disease. Eur J Gastroenterol Hepatol 1997; 9: 939-944 (Pubitemid 27448061)
37. Louis E, Belaiche J, Van Kemseke C, Schaaf N, Mahieu P. Soluble interleukin-2 receptor in Crohn's disease: disease activity assessment and prediction of relapse. Dig Dis Sci 1995; 40: 1750-1756
38. Costa F, Mumolo M, Ceccarelli L, Bellini M, Romano MR, Sterpi C, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005; 54: 364-368 (Pubitemid 40299092)
39. Cellier C, Sahmoud T, Froguel E, Adenis A, Belaiche J, Bretagne JF, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicenter study of 121 cases. Gut 1994; 35: 231-235
40. Ryan E, Heaslip I. Magnetic resonance enteroclysis compared with conventional enteroclysis and computed tomography enteroclysis: a critically appraised topic. Abdom Imaging 2008; 33: 34-37
41. Jones J, Loftus EV Jr, Panaccione R, Chen LS, Peterson S, McConnell J, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 2008; 6: 1218-1224
42. Sipponen T, Savilahti E, Kärkkäinen P, Kolho KL, Nuutinen H, Turunen U, et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis 2008; 14: 1392-1398